Table 2.

Baseline clinical and laboratory data of 177 patients with completed follow-up with further stratification of those with and without progression during the follow-up perioda

ParameterNonprogressors (n = 112)Progressors (n = 65)P
Gender (male/female; n [%])74/38 (66/34)44/21 (68/32)0.83
Age (yr)44.8 ± 12.649.1 ± 11.10.03
Body mass index (kg/m2)24.8 ± 3.525.7 ± 3.90.13
Current smokers (n [%])18 (16)16 (25)0.21
Systolic BP (mmHg)136 ± 22137 ± 170.72
Diastolic BP (mmHg)86 ± 1488 ± 120.34
Serum creatinine (mg/dl)1.54 ± 0.61 (1.14, 1.40, 1.80)3.21 ± 1.31 (2.21, 3.10, 3.94)<0.001
GFR (ml/min per 1.73m2)79 ± 38 (50, 74, 99)38 ± 25 (20, 33, 46)<0.001
Proteinuria (g/24 h per 1.73 m2)0.87 ± 0.95 (0.14, 0.46, 1.25)1.25 ± 0.83 (0.61, 1.09, 1.78)<0.001
Serum albumin (g/dl)4.57 ± 0.434.53 ± 0.360.50
hsCRP (mg/L)0.28 ± 0.320.29 ± 0.310.65
FGF23 c-terminal (rU/ml)92 ± 113 (41, 64, 96)351 ± 394 (96, 190, 492)<0.001
FGF23 intact (pg/ml)35 ± 28 (18, 29, 45)69 ± 70 (31, 48, 80)<0.001
Calcium (mmol/L)2.38 ± 0.22 (2.30, 2.37, 2.44)2.32 ± 0.17 (2.24, 2.31, 2.43)0.04
Phosphate (mmol/L)1.04 ± 0.38 (0.86, 1.01, 1.14)1.25 ± 0.27 (1.02, 1.23, 1.49)<0.001
Ca × P product (mmol2/L2)2.46 ± 0.85 (2.00, 2.37, 2.76)2.90 ± 0.65 (2.43, 2.83, 3.22)<0.001
Parathormone (pmol/L)6.5 ± 5.3 (3.4, 5.0, 7.2)22.5 ± 20.0 (8.0, 16.0, 29.5)<0.001
Use of vitamin D (n [%])9 (8)20 (31<0.001
Use of a phosphate binder (n [%])2 (2)10 (15)0.001
  • a Data are means ± SD and 25th, 50th (median), and 75th percentiles for skewed variables where appropriate.